Home
Brain tumour immunology and therapy group

Main content

Novel method for isolating untouched rat natural killer cells with higher purity compared with positive selection and fluorescence-activated cell sorting. Poli A, Brons NH, Ammerlaan W, Michel T, Hentges F, Chekenya M, Zimmer J. Immunology. 2010 Nov;131(3):386-94.

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Svendsen A, Verhoeff JJ, Immervoll H, Brøgger JC, Kmiecik J, Poli A, Netland IA, Prestegarden L, Planagumà J, Torsvik A, Kjersem AB, Sakariassen PO, Heggdal JI, Van Furth WR, Bjerkvig R, Lund-Johansen M, Enger PO, Felsberg J, Brons NH, Tronstad KJ, Waha A, Chekenya M. Acta Neuropathol. 2011 Aug 24.

Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. Wang J, Svendsen A, Kmiecik J, Immervoll H, Skaftnesmo KO, Planagumà J, Reed RK, Bjerkvig R, Miletic H, Enger PØ, Rygh CB, Chekenya M. PLoS One. 2011;6(7):e23062.

The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Chekenya M, Krakstad C, Svendsen A, Netland IA, Staalesen V, Tysnes BB, Selheim F, Wang J, Sakariassen PØ, Sandal T, Lønning PE, Flatmark T, Enger PØ, Bjerkvig R, Sioud M, Stallcup WB. Oncogene. 2008 Sep 4;27(39):5182-94.

NG2 expression regulates vascular morphology and function in human brain tumours.
Brekke C, Lundervold A, Enger PØ, Brekken C, Stålsett E, Pedersen TB, Haraldseth O, Krüger PG, Bjerkvig R, Chekenya M. Neuroimage. 2006 Feb 1;29(3):965-76.

NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. Chekenya M, Hjelstuen M, Enger PØ, Thorsen F, Jacob AL, Probst B, Haraldseth O, Pilkington G, Butt A, Levine JM, Bjerkvig R. FASEB J. 2002 Apr;16(6):586-8.

 

All publications